Background-The antimigraine drugs ergotamine and sumatriptan may cause
angina-like symptoms, possibly resulting from coronary artery constri
ction. We compared the coronary vasoconstrictor potential of a number
of current and prospective antimigraine drugs (ergotamine, dihydroergo
tamine, methysergide and its metabolite methylergometrine, sumatriptan
, naratriptan, zolmitriptan, rizatriptan, avitriptan). Methods and Res
ults-Concentration-response curves to the antimigraine drugs were cons
tructed in human isolated coronary artery segments to obtain the maxim
um contractile response (E-max) and the concentration eliciting 50% of
E-max (EC50). The EC50 values were related to maximum plasma concentr
ations (C-max) reported in patients, obtaining C-max/EC50 ratios as an
index of coronary vasoconstriction occurring in the clinical setting.
Furthermore, we studied the duration of contractile responses after w
ashout of the acutely acting antimigraine drugs to assess their disapp
earance from the receptor biophase. Compared with sumatriptan, all dru
gs were more potent (lower EC50 values) in contracting the coronary ar
tery but had similar efficacies (E-max <25% of K+-induced contraction)
. The C-max of avitriptan was 7- to 11-fold higher than its EC50 value
, whereas those of the other drugs were <40% of their respective EC50
values. The contractile responses to ergotamine and dihydroergotamine
persisted even after repeated washings, but those to the other drugs d
eclined rapidly after washing. Conclusions-All current and prospective
antimigraine drugs contract the human coronary artery in vitro, but i
n view of low efficacy, these drugs are unlikely to cause myocardial i
schemia at therapeutic plasma concentrations in healthy subjects. In p
atients with coronary artery disease, however, these drugs must remain
contraindicated. The sustained contraction by ergotamine and dihydroe
rgotamine seems to be an important disadvantage compared with sumatrip
tan like drugs.